Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PN20 for Prevention of Chemotherapy-induced Thrombocytopenia
NCT06521931Phase 1Completed
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Jan 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PJ004 in chemotherapy-induced thrombocytopenia (CIT), sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. Primary endpoints: Adverse Events and Proportion of patients with PLT ≥ 100×10^9/L. Started Dec 2023; status: completed.
02
Drugs
PJ004
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT06521931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06521931.